<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02713802</url>
  </required_header>
  <id_info>
    <org_study_id>CUDA-C2015-001</org_study_id>
    <nct_id>NCT02713802</nct_id>
  </id_info>
  <brief_title>Pilot Study of Bioequivalence of Cudafol(R) and Diprivan(R) Administered as Single Intravenous Doses in Healthy Subjects</brief_title>
  <official_title>An Open-Label, Randomized, Two-Way Crossover Pilot Study of the Bioequivalence of Cudafol(R) and Diprivan(R) IV Administered as Single Intravenous Doses in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cuda Anesthetics, LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cuda Anesthetics, LLC</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Evaluate pharmacokinetic/pharmacodynamic equivalence and safety and tolerability of single
      doses of Cudafol(R) and Diprivan(R) in healthy subjects.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2016</start_date>
  <completion_date type="Actual">April 2016</completion_date>
  <primary_completion_date type="Actual">April 2016</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Bioequivalence based on pharmacokinetic parameter: Area Under Curve</measure>
    <time_frame>0-24 hours post dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Bioequivalence based on pharmacokinetic parameter: Cmax</measure>
    <time_frame>0-24 hours post dose</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic parameter: Tmax</measure>
    <time_frame>0-24 hours post dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of adverse events and tolerability</measure>
    <time_frame>7 days post dose</time_frame>
    <description>Number of adverse events and local tolerability</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">8</enrollment>
  <condition>Healthy Subjects</condition>
  <arm_group>
    <arm_group_label>Test product</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Propofol solution (1% [10 mg/mL]), via intravenous injection</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Reference product</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Propofol emulsion (1% [10 mg/mL]), via intravenous injection</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cudafol(R) (propofol, 1% [10 mg/mL])</intervention_name>
    <description>Test product Cudafol(R) to be administered via 1 mg/kg bolus injection, then continuous infusion at 50 ug/kg/min for 15 minutes</description>
    <arm_group_label>Test product</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Diprivan(R) (propofol, 1% [10 mg/mL])</intervention_name>
    <description>Reference product Diprivan(R) to be administered via 1 mg/kg bolus injection, then continuous infusion at 50 ug/kg/min for 15 minutes</description>
    <arm_group_label>Reference product</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Non-obese men and women, 18 to 55 years of age inclusive, and in good health as
             determined by past medical history, physical examination, vital signs,
             electrocardiogram, and laboratory tests at screening. Females of child-bearing
             potential must be using an approved contraceptive method.

        Exclusion Criteria:

          -  Evidence or history of clinically significant disease.

          -  History or presence of clinically significant abnormal 12-lead electrocardiogram
             (ECG), blood pressure, or heart rate.

          -  Pregnant or nursing (lactating) women.

          -  Known hypersensitivity or allergy to propofol (or components of either formulation,
             including eggs, soybean oil or betadex sulfobutyl ether sodium) or any other forms of
             anesthesia, or has had a reaction to anesthesia in the past.

          -  Family history of malignant hyperthermia.

          -  History of drug or alcohol abuse (or tests positive at screening) or current smoker.

          -  Poor venous access in either arm.

          -  Tests positive for hepatitis B surface antigen, hepatitis C virus antibody, or human
             immunodeficiency virus antibody.

        Other protocol defined inclusion/exclusion criteria may apply
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <verification_date>April 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 15, 2016</study_first_submitted>
  <study_first_submitted_qc>March 15, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 21, 2016</study_first_posted>
  <last_update_submitted>April 20, 2016</last_update_submitted>
  <last_update_submitted_qc>April 20, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 21, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Propofol</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

